Oncology | Home | MIMS Malaysia

Malaysia
Search
Sign In

Oncology

Oncology

Home News Diseases Conferences Special Reports Multimedia

Risk of haematological malignancies higher in pernicious anaemia patients

3 days ago

Patients with pernicious anaemia (PA) have a higher risk of biliary tract cancers and haematological malignancies, but a lower risk of cancers other than gastric cancer (GC), according to a new meta-analysis.

Adolescent non-gynae cancer survivors may have increased infertility risk

Roshini Claire Anthony, 4 days ago

Adolescent and young adult female survivors of certain non-gynaecological cancers may have an elevated risk of infertility with parity playing a role in this risk, according to a study from Canada.

NIH, IMU collaboration to boost research, have health impact on Malaysians

Saras Ramiya, 4 days ago

The National Institutes of Health (NIH) and International Medical University (IMU) strengthens their research collaboration with the recent signing of a Memorandum of Understanding (MoU).

Rapid onset opioids for the optimized treatment of breakthrough cancer pain

24 Jul 2018

At a recent dinner symposium held during the Abstral® Grand Launch at Le Meridien Putrajaya, Dr Michael Überall spoke on the management of breakthrough cancer pain (BTcP) and highlighted the role of sublingual fentanyl ([SLF], Abstral®; A. Menarini Pte Ltd) in the optimization of BTcP in cancer patients.

Treatment-free remission: Who, how and why?

21 May 2018

At the recent American Society of Haematology Annual Meeting 2017, Professor François-Xavier Mahon reviewed recent studies related to tyrosine kinase inhibitor (TKI) cessation in patients with chronic myeloid leukaemia (CML) who have achieved sustained deep molecular response (DMR).

Improving survival with CDK4/6 inhibitors in postmenopausal HR+/HER2-metastatic breast cancer patients

Rachel Soon, 28 Feb 2018

Recent developments on CDK 4/6 trials in patients with oestrogen receptor-positive metastatic breast cancers (ER+ MBC) were reviewed at ESMO and ASCO 2017.

Highlights from ESMO Asia 2017: Moving to a dual blockade strategy early in hormone receptor-positive breast cancer

22 Jan 2018

In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia.

Extending survival with sorafenib in locally advanced hepatocellular carcinoma

04 Dec 2017

Management of locally advanced hepatocellular carcinoma aims to improve survival and to maintain the quality of life of patients, with less likelihood of cure due to the advanced nature of disease. Upon diagnosis of the severity of liver cancer, offering appropriate and proven treatment options is important to extend the survival of these patients.

Adolescent non-gynae cancer survivors may have increased infertility risk

Roshini Claire Anthony, 10 Aug 2018

Adolescent and young adult female survivors of certain non-gynaecological cancers may have an elevated risk of infertility with parity playing a role in this risk, according to a study from Canada.

Assisted reproduction not tied to long-term ovarian cancer risk

Roshini Claire Anthony, 04 Aug 2018

Women who undergo assisted reproductive technology (ART) treatment for infertility appear to have an elevated risk of ovarian cancer, but the lack of long-term association suggests that detection bias as well as parity and cause of infertility may play roles and not ovarian stimulating hormones, according to a study from Denmark.

Vitamin D prognostic for Hodgkin’s disease?

Elvira Manzano, 27 Jul 2018

Vitamin D deficiency in patients with Hodgkin’s disease may be a tell-tale sign of what is forbidding to come: poor progression-free survival (PFS) and overall survival (OS), according to an analysis of three studies.

Chemotherapy plus bevacizumab prolongs PFS in recurrent ovarian cancer

Elaine Soliven, 11 Jul 2018

Adding bevacizumab to platinum-based chemotherapy significantly improves progression-free survival (PFS) in patients with recurrent ovarian cancer who were previously treated with first-line bevacizumab, according to the MITO16B - MaNGO OV2B - ENGOT OV17* study presented at ASCO 2018.

Nimotuzumab-CRT improves PFS in head, neck cancers

Audrey Abella, 06 Jul 2018

The addition of the EGFR inhibitor nimotuzumab to a chemoradiotherapy (CRT) regimen using cisplatin improved progression-free survival (PFS) and disease-free survival (DFS) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) compared with CRT alone, according to data from a phase III trial presented at ASCO 2018.

Nephrectomy potentially unnecessary in metastatic kidney cancer

Roshini Claire Anthony, 04 Jul 2018

Patients with metastatic clear-cell renal cell carcinoma (mRCC) who received sunitinib appeared to have comparable overall survival (OS) with those who received sunitinib after undergoing cytoreductive nephrectomy, according to the phase III CARMENA* trial.

Precision medicine extends long-term survival across cancer types

Pearl Toh, 03 Jul 2018

Matching targeted therapy to genetic alterations in the tumour improved response rate and long-term survival in patients with advanced cancer who underwent molecular profiling compared with patients who were unmatched to therapy, highlighting the role of molecular testing in precision medicine, the IMPACT* study shows.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!